MDGL Investigation Reminder: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP

Kessler Topaz Meltzer & Check, LLP is investigating Madrigal Pharmaceuticals for potential securities law violations following a whistleblower complaint filed by the company's former Senior Vice President of Clinical Development. The complaint alleges that Madrigal suppressed adverse liver-injury data, presented unreproducible efficacy results, and allowed an unblinded board member to control clinical outcome adjudication for its only approved drug, Rezdiffra. Following the disclosure, Madrigal's stock price fell over 8%.